Desmosine as a biomarker of elastin degradation in COPD: Current status and future directions

European Respiratory Journal

Volumn 32, Issue 5, 2008, Pages 1146-1157

  Luisetti, M ^a,c   Ma, S ^b   Iadarola, P ^c   Stone, P J ^d   Viglio, S ^c   Casado, B ^e   Lin, Y Y ^b   Snider, G L ^f   Turino, G M ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF PAVIA   (Italy)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NESTLÉ RESEARCH CENTER   (Switzerland)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Body fluids; Capillary electrophoresis; Elastin peptides; HPLC; Laser induced fluorescence; Mass spectrometry

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; DESMOSINE; ELASTIN; ISODESMOSINE; PEPTIDE; PYRIDINIUM DERIVATIVE; TROPOELASTIN;

ALPHA ANTITRYPSIN DEFICIENCY; AMINO ACID ANALYSIS; BODY FLUID; CAPILLARY ELECTROPHORESIS; CHEMICAL STRUCTURE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CROSS LINKING; DRUG EXCRETION; ELASTIC FIBER; ENZYME LINKED IMMUNOSORBENT ASSAY; FUTUROLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOFLUORESCENCE; LASER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; MONITORING; PERFORMANCE; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN METABOLISM; RADIOIMMUNOASSAY; REVIEW; SMOKING; SPUTUM; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; URINE;

ADULT; ALPHA 1-ANTITRYPSIN DEFICIENCY; CHILD; CHROMATOGRAPHY, LIQUID; DESMOSINE; ELASTIN; FEMALE; HUMANS; ISODESMOSINE; MALE; MODELS, BIOLOGICAL; PEPTIDES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TANDEM MASS SPECTROMETRY;

EID: 58849150305     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00174807     Document Type: Review

References (67)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-1243.
2. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 188-207.
3. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
4. 1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
5. Cohen AB. Introduction. In: AB Cohen, ed. Pulmonary Emphysema. The Rationale for Therapeutic Intervention. Ann NY Acad Sci 1991; 624S: 1-5.
6. Rosenbloom J, Campbell EJ, Mumford R, et al. Biochemical/ immunologic markers of emphysema. In: AB Cohen, ed. Pulmonary Emphysema. The Rationale for Therapeutic Intervention. Ann NY Acad Sci 1991; 624S: 7-12.
7. Rosenbloom J, Abrams WR, Mecham R. Extracellular matrix 4: the elastic fiber. FASEB J 1993; 7: 1208-1218.
8. Foster JA, Curtiss SW. The regulation of lung elastin synthesis. Am J Physiol 1990; 259: L13-L23.
9. Schriver EE, Davidson JM, Sutcliffe MC, Swindell BB, Bernard GR. Comparison of elastin peptide concentrations in body fluids from healthy volunteers, smokers, and patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145: 762-766.
10. Kucich U, Christner P, Lippmann M, et al. Utilization of a peroxidase antiperoxidase complex in an enzyme-linked immunosorbent assay of elastin-derived peptides in human plasma. Am Rev Respir Dis 1985; 131: 709-713.
11. Watanabe T, Ishimori K, Verplanke AJ, Matsuki H, Kasuga H. An enzyme-linked immunosorbent assay (ELISA) for the quantitation of urinary desmosine. Tokai J Exp Clin Med 1989; 14: 347-356.
12. King GS, Mohan VS, Starcher BC. Radioimmunoassay for desmosine. Connect Tissue Res 1980; 7: 263-267.
13. Darnule TV, McKee M, Darnule AT, Turino GM, Mandl I. Solid-phase radioimmunoassay for estimation of elastin peptides in human sera. Anal Biochem 1982; 122: 302-307.
14. Starcher B, Green M, Scott M. Measurement of urinary desmosine as an indicator of acute pulmonary disease. Respiration 1995; 62: 252-257.
15. Stone PJ, Bryan-Rhafdi J, Lucey EC, et al. Measurement of urinary desmosine by isotope dilution and high performance liquid chromatography. Correlation between elastase-induced air-space enlargement in the hamster and elevation of urinary desmosine. Am Rev Respir Dis 1991; 144: 284-290.
16. Stone PJ, Lucey EC, Snider GL, Franzblau C. Effect of diet on urinary excretion of desmosine and hydroxylysyl pyridinoline. Am J Respir Crit Care Med 1994; 149: 174-177.
17. Viglio S, Zanaboni G, Luisetti M, et al. Micellar electrokinetic chromatography for the determination of urinary desmosine and isodesmosine in patients affected by chronic obstructive pulmonary disease. J Chromatogr B Biomed Sci Appl 1998; 714: 87-98.
18. Viglio S, Iadarola P, Lupi A, et al. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J 2000; 15: 1039-1045.
19. Ma S, Lieberman S, Turino GM, Lin YY. The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum. Proc Natl Acad Sci USA 2003; 100: 12941-12943.
20. Viglio S, Annovazzi L, Luisetti M, Stolk J, Casado B, Iadarola P. Progress in the methodological strategies for the detection in real samples of desmosine and isodesmosine, two biological markers of elastin degradation. J Sep Sci 2007; 30: 202-213.
21. Goldstein RA, Starcher BC. Urinary excretion of elastin peptides containing desmosine after intratracheal injection of elastase in hamsters. J Clin Invest 1978; 61: 1286-1290.
22. Janoff A, Chanana AD, Joel DD, et al. Evaluation of the urinary desmosine radioimmunoassay as a monitor of lung injury after endobronchial elastase instillation in sheep. Am Rev Respir Dis 1983; 128: 545-551.
23. Davies SF, Offord KP, Brown MG, Campe H, Niewoehner D. Urine desmosine is unrelated to cigarette smoking or to spirometric function. Am Rev Respir Dis 1983; 128: 473-475.
24. Harel S, Janoff A, Yu SY, Hurewitz A, Bergofsky EH. Desmosine radioimmunoassay for measuring elastin degradation in vivo. Am Rev Respir Dis 1980; 122: 769-773.
25. Stone PJ, Gottlieb DJ, O'Connor GT, et al. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 952-959.
26. Gottlieb DJ, Stone PJ, Sparrow D, et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am J Respir Crit Care Med 1996; 154: 1290-1295.
27. Bode DC, Pagani ED, Cumiskey WR, von Roemeling R, Hamel L, Silver PJ. Comparison of urinary desmosine excretion in patients with chronic obstructive pulmonary disease or cystic fibrosis. Pulm Pharmacol Ther 2000; 13: 175-180.
28. 1- antitrypsin deficiency, a phenotype associated with hereditary predisposition to pulmonary emphysema. Am Rev Respir Dis 1985; 132: 821-823.
29. Cohen AB, Girard W, McLarty J, et al. A controlled trial of colchicine to reduce the elastase load in the lungs of cigarette smokers with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 142: 63-72.
30. Cohen AB, Girard W, McLarty J, et al. A controlled trial of colchicine to reduce the elastase load in the lungs of excigarette smokers with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1038-1043.
31. Stevens MD, Miller EJ, Cohen AB. Search for drugs that may reduce the load of neutrophil azurophilic granule enzymes in the lungs of patients with emphysema. Exp Lung Res 1989; 15: 663-680.
32. Luisetti M, Sturani C, Sella D, et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996; 9: 1482-1486.
33. Baici A, Pelloso R, Hörler D. The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound. Biochem Pharmacol 1990; 39: 919-924.
34. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for a1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062.
35. 1-antitrypsin-deficient humans. Respiration 1995; 62: 76-79.
36. 1-antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med 2000; 162: 2069-2072.
37. 1-antitrypsin, Respitin. Chest 2002; 122: 66-74.
38. Ma S, Lin YY, Turino GM. Measurement of desmosine and isodesmosine by mass spectrometry in COPD. Chest 2007; 131: 1363-1371.
39. Rodriguez JR, Seals JE, Radin A, Lin JS, Mandl I, Turino GM. Neutrophil lysosomal elastase activity in normal subjects and in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1979; 119: 409-417.
40. Cantor JO, Cerreta JM, Ochoa M, et al. Aerosolized hyaluronan limits airspace enlargement in a mouse model of cigarette smoke-induced pulmonary emphysema. Exp Lung Res 2005; 31: 417-430.
41. Ma S, Lin YY, Turino GM. The effect of tiotropium (TIO) on levels of desmosine and isodesmosine (D/I) in urine, plasma, and sputum in COPD. Eur Respir J 2007; 30: Suppl. 51, 355s.
42. Akagawa M, Suyama K. Mechanism of formation of elastin crosslinks. Connect Tissue Res 2000; 41: 131-141.
43. Annovazzi L, Viglio S, Perani E, et al. Capillary electrophoresis with laser-induced fluorescence detection as a novel sensitive approach for the analysis of desmosines in real samples. Electrophoresis 2004; 25: 683-691.
44. Annovazzi L, Viglio S, Gheduzzi D, et al. High levels of desmosines in urine and plasma of patients with Pseudoxanthoma elasticum. Eur J Clin Invest 2004; 34: 156-164.
45. 1-antitrypsin deficiency. Respir Res 2005; 6: 47.
46. Boschetto P, Quintavalle S, Zeni E, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006; 61: 1037-1042.
47. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995; 152: 157-162.
48. Cocci F, Miniati M, Monti S, et al. Urinary desmosine excretion is inversely correlated with the extent of emphysema in patients with chronic obstructive pulmonary disease. Int J Biochem Cell Biol 2002; 34: 594-604.
49. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 367-370.
50. Starcher B, Peterson B. The kinetics of elastolysis: elastin catabolism during experimentally induced fibrosis. Exp Lung Res 1999; 25: 407-424.
51. Fiorenza D, Viglio S, Lupi A, et al. Urinary desmosine excretion in acute exacerbations of COPD: preliminary report. Respir Med 2002; 96: 110-114.
52. Fregonese L, Ferrari F, Fumagalli M, et al. Ventilation inhomogeneity is correlated with biomarkers of parenchymal destruction in a1-antitrypsin deficiency. Eur Respir J 2007; 30: Suppl. 51, 620s.
53. Gelb AF, Hogg JC, Müller NL, et al. Contribution of emphsyema and small airways in COPD. Chest 1996; 109: 353-359.
54. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102-1108.
55. Baldi S, Miniati M, Bellina CR, et al. Relationship between extent of pulmonary emphysema by high-resolution computed tomography and lung elastic recoil in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 585-589.
56. Fregonese L, Fumagalli M, Ferrari F, Luisetti M, Iadarola P, Stolk J. Long-term changes of elastin breakdown products in a1-antitrypsin deficiency. Eur Respir J 2007; 30: Suppl. 51, 140s.
57. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 258-266.
58. Newell JD Jr, Hogg JC, Snider GL. Report of a workshop: quantitative computed tomography scanning in longitudinal studies of emphysema. Eur Respir J 2004; 23: 769-775.
59. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
60. 1-antitrypsin deficiency. Am J Respir Crit Care Med 2002; 165: 1494-1498.
61. Osman M, Keller S, Hosannah Y, Cantor JO, Turino GM, Mandl I. Impairment of elastin resynthesis in the lungs of hamsters with experimental emphysema induced by sequential administration of elastase and trypsin. J Lab Clin Med 1985; 105: 254-258.
62. Osman M, Kaldany RR, Cantor JO, Turino GM, Mandl I. Stimulation of lung lysyl oxidase activity in hamsters with elastase-induced emphysema. Am Rev Respir Dis 1985; 131: 169-170.
63. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 6-14.
64. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31: 869-873.
65. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-832.
66. Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax 2007; 62: 657-660.
67. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.